Vera Therapeutics (NASDAQ:VERA) Shares Down 7.4% – Here’s Why

Vera Therapeutics, Inc. (NASDAQ:VERA)’s stock price fell 7.4% during trading on Monday . The company traded as low as $45.55 and last traded at $45.1160. 538,975 shares were traded during trading, a decline of 48% from the average session volume of 1,035,229 shares. The stock had previously closed at $48.71.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vera Therapeutics in a research note on Wednesday, November 26th. Wedbush upped their price objective on Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. HC Wainwright reiterated a “buy” rating and set a $90.00 price objective on shares of Vera Therapeutics in a report on Friday, November 28th. Bank of America boosted their target price on Vera Therapeutics from $48.00 to $66.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Finally, The Goldman Sachs Group upped their price target on Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $74.83.

Vera Therapeutics Price Performance

The stock has a market cap of $2.97 billion, a price-to-earnings ratio of -11.64 and a beta of 1.16. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21. The company has a 50-day simple moving average of $40.18 and a two-hundred day simple moving average of $30.24.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Wednesday, November 5th. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same quarter last year, the company earned ($0.85) EPS. As a group, equities research analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Insider Transactions at Vera Therapeutics

In related news, SVP Joseph R. Young sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $29.06, for a total value of $435,900.00. Following the completion of the sale, the senior vice president directly owned 47,839 shares in the company, valued at approximately $1,390,201.34. This trade represents a 23.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Patrick G. Enright purchased 5,882 shares of the stock in a transaction on Thursday, December 11th. The shares were acquired at an average cost of $42.50 per share, for a total transaction of $249,985.00. Following the transaction, the director owned 5,882 shares of the company’s stock, valued at approximately $249,985. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 16.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Vera Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its holdings in Vera Therapeutics by 50.5% in the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after acquiring an additional 236 shares during the period. Quantbot Technologies LP acquired a new position in shares of Vera Therapeutics in the second quarter valued at approximately $51,000. Virtus Investment Advisers LLC increased its stake in shares of Vera Therapeutics by 14.8% during the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock worth $98,000 after purchasing an additional 539 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Vera Therapeutics by 192.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after purchasing an additional 2,757 shares during the last quarter. Finally, Fifth Third Bancorp bought a new stake in Vera Therapeutics in the 2nd quarter valued at $102,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.